Multiple Sclerosis Therapeutics, Second Edition
2nd Edition
Published on 16. January 2003
Book
Hardback
758 pages
978-1-84184-226-4 (ISBN)
Description
This revised textbook examines the most important aspects of multiple sclerosis that impact on clinical trial design, on the development of new disease therapies, and, most importantly, on patient care. An international team of contributors discusses the clinical course of multiple sclerosis, its clinical heterogeneity, and the presence of subclinical disease activity which occurs during the early stages of the disease. There have been substantial advances in the field since the first edition was published in 1999. There are new chapters on functional imaging, the issues involved in long-term follow-up studies, cyclophosphamide, sex hormones and pregnancy-related factors, complementary and alternative treatments, management of cognitive impairment, treatment of pain, and rehabilitative approaches. Chapters on MS pathogenesis, imaging, the interferons, glatiramer acetate, mitoxantrone, IVIg, plasma exchange, stem cell transplantation, combination therapies, and newly-emerging treatments have been updated. This book is essential for any clinician who works with MS patients.
More details
Edition
2nd New edition
Language
English
Place of publication
London
United Kingdom
Publishing group
Taylor & Francis Ltd
Target group
College/higher education
Professional and scholarly
Edition type
New edition
Illustrations
74 s/w Abbildungen
74 Illustrations, black and white
Dimensions
Height: 235 mm
Width: 187 mm
Weight
1837 gr
ISBN-13
978-1-84184-226-4 (9781841842264)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
New editions
Book
03/2007
3rd Edition
CRC Press
€416.65
Shipment within 3-4 weeks
Persons
Content
Part I: Introduction. Aspects of Multiple Sclerosis that Relate to Clinical Trial Design and Treatment. Part II: Clinical Trial Methodology. Measures of Impairment and Disability. Assessment of Neuropsychological Function. Health-related Quality of Life Assessment in Multiple Sclerosis. Magnetic Resonance Imaging in Multiple Sclerosis: an Overview. Measures of Gadolinium Enhancement. Measures of Magnetization Transfer. Measures of T1 and T2 Relaxation. Measurement of CNS Atrophy. Measures to Quantify Axonal Damage In Vivo Based on Magnetic Resonance Spectroscopy. Functional Imaging in Multiple Sclerosis. The Use of Cost Analyses to Improve our Understanding of Therapeutic Trade-offs for Multiple Sclerosis. Ethical Considerations in Multiple Sclerosis Clinical Trials. The Process of Drug Development and Approval in the United States, European Union, and Canada. Sponsors, Monitoring Committees, and Investigators: the Investigator's Perspective. Guidelines for Clinical Trials of New Therapeutic Agents in Multiple Sclerosis: Reporting Extended Results from Phase III Clinical Trials. The Failed Clinical Trial. The Challenge of Long-term Studies in MS: Use of Pooled Data, Historical Controls, and Observational Studies to determine efficacy. Part III: Clinical Trials of Disease Modifying Therapy. Emerging Concepts of Pathogenesis: Relationship to MS Therapies. Interferons in Relapsing Remitting MS. Interferons in Secondary Progressive MS. Biologic Mechanisms of Action of Interferons in MS. Glatiramer Acetate. Mitoxantrone. Intravenous Immunoglobin to Treat Multiple Sclerosis. Therapeutic Plasma Exchange for Multiple Sclerosis. Methylprednisolone. Cyclophosphamide Treatment of Multiple Sclerosis. Treatment of Multiple Sclerosis by Hematopoietic Stem Cell Transplantation. Emerging Disease-modifying Therapies. Combination Therapies in Multiple Sclerosis. Sex Hormones and Other Pregnancy Related Factors with Therapeutic Potential in Multiple Sclerosis. Complementary and Alternative Treatments in Multiple Sclerosis. Part IV: Therapy in Clinical Practice. Use of Disease-modifying Drug Therapy for Relapsing Forms of MS in Clinical Practice. Primary Progressive MS. Fatigue. Management of Spasticity in Multiple Sclerosis. Bladder and Sexual Dysfunction. Treatment of Disorders of Mood and Affect. Pain and Paroxysmal Disorders. Tremor. Management of Cognitive Impairment in MS. Rehabilitation in Multiple Sclerosis Patients Sclerosis that Relate to Clinical Trial Design and Treatment. Part II: Clinical Trial Methodology. Measures of Impairment and Disability. Assessment of Neuropsychological Function. Health-related Quality of Life Assessment in Multiple Sclerosis. Magnetic Resonance Imaging in Multiple Sclerosis: an Overview. Measures of Gadolinium Enhancement. Measures of Magnetization Transfer. Measures of T1 and T2 Relaxation. Measurement of CNS Atrophy. Measures to Quantify Axonal Damage In Vivo Based on Magnetic Resonance spectroscopy. Functional Imaging in Multiple Sclerosis. Bodily Fluid Markers for Disease Course and Activity. The Use of Cost Analyses to Improve our Understanding of Therapeutic Trade-offs for Multiple Sclerosis. Ethical Considerations in Multiple Sclerosis Clinical Trials. The Process of Drug Development and Approval in the United States, European Union, and Canada. Sponsors, Monitoring Committees, and Investigators: the Investigator's Perspective. Guidelines for Clinical Trials of New Therapeutic Agents in Multiple Sclerosis: Reporting Extended Results from Phase III Clinical Trials. The Failed Clinical Trial. The Challenge of Long-term Studies in MS: Use of Pooled Data, Historical Controls, and Observational Studies to Determine Efficacy. Part III Clinical Trials of Disease Modifying Therapy. Emerging Concepts of Pathogenesis: Relationship to MS Therapies. Interferons in Relapsing Remitting MS. Interferons in Secondary Progressive MS. Biologic Mechanisms of Action of Interferons in MS.